Patents Examined by Karlheinz R. Skowronek
  • Patent number: 9205135
    Abstract: Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are indentified.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: December 8, 2015
    Assignee: University of Miami
    Inventor: Jochen Reiser
  • Patent number: 9206237
    Abstract: Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin ?v?6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in ?v?6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin ?v?6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: December 8, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard H. Kimura, Sanjiv S. Gambhir, Benjamin J. Hackel, Robert Teed, Bin Shen, Frederick T Chin, Zhen Cheng
  • Patent number: 9206239
    Abstract: Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: December 8, 2015
    Assignee: PIN PHARMA, INC.
    Inventor: David I. Cohen
  • Patent number: 9206224
    Abstract: Method for assembling proteins from peptide fragments. It allows the production of proteins in a manner that is simple, reliable and applicable on an industrial scale. This method allows the production of proteins of therapeutic or diagnostic interest. The invention also relates to kits for applying this synthesis method as well as test and/or diagnostic kits.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: December 8, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Oleg Melnyk, Laurent Raibaut, Vincent Aucagne, Agnes Delmas
  • Patent number: 9206222
    Abstract: The present invention relates to the synthesis of depsipeptides on solid phase support. Said depsipeptides are then implicated in a solution phase O—N acyl shift enabling to obtain the corresponding peptide alcohols.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: December 8, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Muriel Caussil-Amblard, Jean Martinez, Julien Tailhades
  • Patent number: 9198971
    Abstract: The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions according to the invention also comprise a prandial insulin and/or gut hormone.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 1, 2015
    Assignee: ADOCIA
    Inventor: Olivier Soula
  • Patent number: 9200051
    Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-?MePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 SEQ ID NO: 1 (I) wherein each symbol is as defined herein.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 1, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Taiji Asami, Ayumu Niida
  • Patent number: 9198956
    Abstract: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 1, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Nicholas F. LaRusso, Tetyana V. Masyuk, Melissa Muff-Luett
  • Patent number: 9200082
    Abstract: Embodiments of the invention are directed to fibrillar adjuvants. For example, epitopes assembled by a synthetic peptide domain into nanofibers comprising a ?-fibrillization peptide may elicit high antibody titers in the absence of any adjuvant. In certain embodiments, multiple different antigens may be integrated into polypeptide nanofibers, providing biomaterials with modular and precise composition of bioactive proteins.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 1, 2015
    Assignee: The University of Chicago
    Inventors: Joel Collier, Gregory Hudalla
  • Patent number: 9200114
    Abstract: The present invention relates to a synthetic polypeptide which is a random linear pentapolymer comprising alanine, glutamic acid, lysine, tyrosine and phenylalanine and use thereof in treating autoimmune diseases, in particular multiple sclerosis.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: December 1, 2015
    Assignee: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • Patent number: 9193775
    Abstract: The present technology relates to well-defined oligomers comprising two or more monomers wherein each monomer is independently selected from a ubiquitin polypeptide or a ubiquitin-like polypeptide, and the monomers are covalently linked to each other via a thioether group or groups. Further provided are monomer building blocks and methods of making the monomers and oligomers.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: November 24, 2015
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Eric Strieter, Ellen Valkevich, Robert Guenette
  • Patent number: 9194870
    Abstract: The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: November 24, 2015
    Assignee: ABAXIS, INC.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Andrew P. Rogers, Timothy P. Forsyth, Jeremy D. Walker, Christina R. Cuesico
  • Patent number: 9192624
    Abstract: The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: November 24, 2015
    Assignee: AJINOMOTO CO., INC.
    Inventors: Manabu Kitazawa, Satoru Ohashi, Yoko Masuzawa, Kousaku Ohkawa, Yasuhiko Tabata
  • Patent number: 9187555
    Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilized to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: November 17, 2015
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
  • Patent number: 9187551
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 17, 2015
    Assignee: Cerenis Therapeutics Holding S.A.
    Inventors: Jean-Louis Dasseux, Rose Ackermann
  • Patent number: 9186349
    Abstract: The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising alicyclic diaza compounds, including 1,2 diaza heterocyclic compounds, having a photolabile N—N bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic aromatic group. In some embodiments, for example, the invention provides alicyclic diaza compounds for phototherapeutic methods having a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species, such as radicals, ions, etc., that achieve a desired therapeutic effect, such as selective and/or localized tissue damage and/or cell death.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 17, 2015
    Assignee: Mallinckrodt LLC
    Inventor: Raghavan Rajagopalan
  • Patent number: 9187525
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: November 17, 2015
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Patent number: 9186389
    Abstract: The present invention provides a nanoparticle and cell delivery agent, capable of releasing a target substance in a weakly acidic pH environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with His (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: November 17, 2015
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Kentaro Kogure, Susumu Hama
  • Patent number: 9186673
    Abstract: Multi-well plates having contoured well designs allow multi-stage high throughput parallel assaying of ion channels or ion transporters. A well of a multi-well plate has a bottom region that is sized and shaped to simultaneously accommodate a sensing electrode and a pipette for delivering test compounds, wash fluid, and optionally ligands. The multi-well plates when coupled with an instrument having a pipette head and an electrode plate facilitates fluidic contact between cells and fluids delivered via a pipette for washing of wells with buffers or other wash solutions for serial exposure of test cells to various reagents or other stimuli. The control and test experiments are performed on the same cell (or cells) in a single well.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 17, 2015
    Assignee: Molecular Devices, LLC
    Inventor: Edward D. Verdonk
  • Patent number: 9181542
    Abstract: The present invention relates to a method for increasing chaperone activity by irradiating peroxiredoxin (Prx) proteins. More particularly, the present invention may be useful for preparing recombinant proteins imparting resistance against various environmental stresses by increasing the chaperone activity of peroxiredoxin, since it has been observed that irradiated peroxiredoxin has enhanced chaperone activity characteristics, wherein an ?-helix structure decreases while a ?-sheet structure increases, from analysis results of a protein structure change and chaperone activity after irradiating two types of peroxiredoxins (2-Cys, 3-Cys) which are two active cysteine motifs of peroxiredoxin.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: November 10, 2015
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Byung Yeoup Chung, Seung Sik Lee, Byung Chull An, Eun Mi Lee, Jae Taek Lee, Hyoung-Woo Bai